Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00494013 | Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) | PHASE3 | COMPLETED | 442 | — | — | Aug 1, 2007 | Sep 1, 2008 | Nov 11, 2009 | 56 | United States, Argentina +7 |
| Arm | Type | Description |
|---|---|---|
| Insulin Lispro Protamine Suspension | EXPERIMENTAL | Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks. |
| Detemir | ACTIVE_COMPARATOR | Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks. |
| Name | Type | Description |
|---|---|---|
| Insulin Lispro Protamine Suspension | DRUG | Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks. |
| Detemir | DRUG | Patient specific dose administered subcutaneously once or twice daily x 24 weeks. |
Inclusion Criteria: 1. Have type 2 diabetes mellitus for at least 1 year. 2. Are at least 18 years old. 3. Have been receiving oral antihyperglycemic medications (OAMs), without insulin, for at least 3 months immediately prior to the study and have been on stable doses of at least 2 of the followin...